Kintegral Advisory LLC Sells 57 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Kintegral Advisory LLC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,210 shares of the biopharmaceutical company’s stock after selling 57 shares during the quarter. Kintegral Advisory LLC’s holdings in Regeneron Pharmaceuticals were worth $862,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Drum Hill Capital LLC bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $214,000. Centricity Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $67,000. ING Groep NV boosted its position in shares of Regeneron Pharmaceuticals by 33.7% in the 4th quarter. ING Groep NV now owns 29,085 shares of the biopharmaceutical company’s stock worth $20,718,000 after purchasing an additional 7,324 shares in the last quarter. Hussman Strategic Advisors Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $1,496,000. Finally, Private Advisor Group LLC grew its stake in shares of Regeneron Pharmaceuticals by 129.8% in the 4th quarter. Private Advisor Group LLC now owns 12,319 shares of the biopharmaceutical company’s stock worth $8,774,000 after buying an additional 6,958 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the topic of several analyst reports. Wolfe Research started coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price on the stock. Barclays dropped their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Oppenheimer reduced their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. TD Cowen dropped their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. Finally, BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $700.33 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a 50-day simple moving average of $699.40 and a two-hundred day simple moving average of $882.47. The firm has a market capitalization of $76.56 billion, a PE ratio of 18.29, a P/E/G ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $11.86 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.